August, 2024
August 2024
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Myeloma Paper of the Day, August 12th, suggested by Robert Orlowski
Aug 12, 2024, 10:33

Myeloma Paper of the Day, August 12th, suggested by Robert Orlowski

Robert Orlowski shared on X:

Myeloma Paper of the Day: Nationwide population-based study in South Korea finds increasing incidence and prevalence of myeloma, and improving survival with greater use of novel agents, though median survival time was still only 3.36 years.

Source: Robert Orlowski/X

Trends in multiple myeloma incidence, prevalence, mortality, and survival rate in South Korea: a nationwide population-based study

Authors: Boyoung Park, Junghyun Yoon, YooSun Lee, YoungJu Park and Hyeon-Seok Eom.

Myeloma Paper of the Day, August 12th, suggested by Robert Orlowski

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.